SREBP-2 Inhibitors
Common SREBP-2 Inhibitors include, but are not limited to Betulinic Acid CAS 472-15-1, Mevastatin (Compactin) CAS 73573-88-3, 25-Hydroxycholesterol CAS 2140-46-7, 7-Ketocholesterol CAS 566-28-9 and YM-53601 CAS 182959-33-7.
SREBP-2 inhibitors belong to a chemical class designed to modulate the activity of Sterol Regulatory Element-Binding Protein 2 (SREBP-2). SREBP-2 is a transcription factor that plays a pivotal role in regulating the synthesis and uptake of cholesterol in cells. This protein is a key player in the complex network of lipid metabolism and homeostasis. It operates by controlling the expression of genes involved in cholesterol biosynthesis and uptake pathways.
Inhibitors within the SREBP-2 class are developed to interfere with the function of SREBP-2, thereby disrupting the regulatory cascade that controls cholesterol metabolism. By targeting SREBP-2, these inhibitors have the ability to modulate cellular cholesterol levels and impact lipid homeostasis. Research into SREBP-2 inhibitors can shed light on the intricate mechanisms underlying cholesterol regulation, which is crucial for maintaining cellular health and preventing cholesterol-related disorders. These inhibitors provide a means to investigate the role of SREBP-2 in cellular physiology and its implications for metabolic pathways beyond cholesterol metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fatostatin | 125256-00-0 | sc-507496 | 100 mg | $450.00 | ||
Binds to SCAP and inhibits the SCAP-SREBP interaction, preventing SREBP-2 activation and subsequent cholesterol synthesis. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Reduces SREBP-2 expression and nuclear translocation, leading to decreased cholesterol biosynthesis. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $77.00 $179.00 | 18 | |
Statin drug inhibiting HMG-CoA reductase, indirectly lowering cholesterol synthesis and activating SREBP-2 feedback. | ||||||
25-Hydroxycholesterol | 2140-46-7 | sc-214091B sc-214091 sc-214091A sc-214091C | 5 mg 10 mg 25 mg 100 mg | $53.00 $91.00 $169.00 $474.00 | 8 | |
Acts as an oxysterol that binds to INSIG-1 and -2, promoting SREBP-2 degradation and reducing cholesterol synthesis. | ||||||
7-Ketocholesterol | 566-28-9 | sc-210630 | 5 mg | $99.00 | 5 | |
Another oxysterol that triggers SREBP-2 degradation via INSIG-1 and -2, inhibiting cholesterol biosynthesis. | ||||||
YM-53601 | 182959-33-7 | sc-205543 sc-205543A | 500 µg 1 mg | $336.00 $480.00 | 3 | |
Inhibits the proteolytic processing of SREBP-2 precursors, preventing their activation and reducing cholesterol synthesis. | ||||||
PF-429242 | 947303-87-9 | sc-507498 | 5 mg | $176.00 | ||
Inhibits S1P, impacting SREBP-2 cleavage and activation, and lowering cholesterol biosynthesis. | ||||||
LP 922056 | 1365060-22-5 | sc-507098 sc-507098A | 5 mg 25 mg | $165.00 $700.00 | ||
Interferes with SREBP-2 processing and its translocation to the nucleus, decreasing cholesterol synthesis. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $51.00 $71.00 $199.00 | 11 | |
Suppresses SREBP-2 activation by inhibiting AMPK-mediated phosphorylation, reducing cholesterol biosynthesis. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $116.00 $230.00 | 12 | |
Disrupts SREBP-2 processing and its nuclear translocation, leading to decreased cholesterol synthesis. | ||||||